Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 6/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042497 | 0.92 | HTT (0.42) | PLA2G2APTPN11TSHRBRD4MCL1 | |
| SCHEMBL7167199 | 0.87 | TSHR (0.48) | PLA2G2APTPN11TP53TSHRBRD4 | |
| SCHEMBL7114606 | 0.78 | ALDH1A1 (0.43) | TSHRBRD4 | |
| SCHEMBL6873797 | 0.77 | GAA (0.45) | TP53TSHR | |
| SCHEMBL6879965 | 0.72 | METAP2 (0.38) | TSHR | |
| SCHEMBL8085899 | 0.72 | PTPN11 (0.68) | PLA2G2APTPN11TP53TSHRPLA2G4B | |
| SCHEMBL23748612 | 0.71 | PLA2G2A (0.56) | PLA2G2APTPN11TP53TSHRPLA2G4B | |
| SCHEMBL23352171 | 0.71 | PLA2G2A (0.56) | PLA2G2APTPN11TP53TSHRPLA2G4B | |
| SCHEMBL29173955 | 0.71 | PLA2G2A (0.56) | PLA2G2APTPN11TP53TSHRPLA2G4B | |
| SCHEMBL12921977 | 0.71 | BRD4 (0.66) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087655-A1 | 6-Substituted indanoyl amino acid conjugates as mimics to the biological activity of coronatine | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV (DE) | 2004-05-06 | — | — | US | disclosed |
| EP-1351922-A2 | 6-SUBSTITUTED INDANOYL AMINO ACID CONJUGATES AS MIMICS TO THE BIOLOGICAL ACTIVITY OF CORONATINE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055480-A2 | 6-SUBSTITUTED INDANOYL AMINO ACID CONJUGATES AS MIMICS TO THE BIOLOGICAL ACTIVITY OF CORONATINE | MAX PLANCK GESELLSCHAFT (DE) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087655-A1 | 6-Substituted indanoyl amino acid conjugates as mimics to the biological activity of coronatine | CORO1C, CORO1A, AGER | PLA2G2A 1408/4885PTPN11 3471/4885TP53 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.